The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

"Spravato" can be used on its own by people who don't respond to traditional depression medication. Against the odds, Prince ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use ...

The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe depression. It is now the first-ever stand-alone therapy for treatment-resistant ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

US healthcare giant Johnson & Johnson announced the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Spravato (esketamine) CIII nasal spray as the first ...

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...